- Sirona Biochem (SBM) terminates supply agreement with Rodan + Fields
- Allergan Aesthetics will now be the sole licensee of the technology as per the agreement signed in June 2022
- There may be potential for more news to be released regarding this termination at a later date
- Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology
- The company strives to patent new compounds for maximum revenue potential
- Sirona Biochem (SBM) is up 23.81 per cent, trading at C$0.13 at 1:57 pm EST
Sirona Biochem (SBM) has terminated the Rodan + Fields (R+F) agreement for the supply and use of TFC-1067 in commercial formulations.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will now be the sole licensee of the technology as per the agreement signed in June 2022.
There may be more news regarding the termination at a later date.
Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology.
Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety.
The company strives to patent new compounds for maximum revenue potential.
Sirona Biochem (SBM) is up 23.81 per cent, trading at C$0.13 at 1:57 pm EST.